Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 0.56 |
| ▸ | INSR | P06213 | 5/20 | 0.49 |
| ▸ | LCK | P06239 | 5/20 | 0.49 |
| ▸ | LYN | P07948 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | HCK | P08631 | 4/20 | 0.49 |
| ▸ | RAF1 | P04049 | 4/20 | 0.49 |
| ▸ | ARAF | P10398 | 4/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152879 | 0.92 | BRAF (0.55) | BRAFINSRLCKLYNSRC | |
| SCHEMBL1825894 | 0.92 | BRAF (0.58) | BRAFINSRLCKLYNSRC | |
| SCHEMBL1841461 | 0.90 | BRAF (0.69) | BRAFINSRLCKLYNSRC | |
| SCHEMBL3229925 | 0.87 | BRAF (0.66) | BRAFINSRLCKLYNSRC | |
| SCHEMBL22337466 | 0.87 | ABL1 (0.58) | BRAFINSRLCKLYNSRC | |
| SCHEMBL3241401 | 0.86 | BRAF (0.57) | BRAFHCKMAPK14 | |
| SCHEMBL1833165 | 0.86 | LCK (0.66) | BRAFINSRLCKLYNSRC | |
| SCHEMBL3236564 | 0.85 | BRAF (0.62) | BRAFINSRLCKLYNSRC | |
| SCHEMBL3234843 | 0.85 | LCK (0.66) | BRAFINSRLCKLYNSRC | |
| SCHEMBL3236575 | 0.84 | BRAF (0.58) | BRAFINSRLCKLYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | BRAF 206/4885INSR 1411/4885LCK 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.